Healthcare · Biotechnology
Price
$4.13
Market Cap
$353.4M
Employees
65
Beta
0.84
Avg Volume
2,094,239
CEO
Carole S. Ben-Maimon
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Runs with full report
Price Overview
Last updated: Jul 10, 2026 1:48am (just now)
Current data · timestamped when a report runs
$4.13
Change · Jul 10
+0.52 (+14.40%)
Day Range
$3.80 – $4.28
52-Week Range
$2.72 – $6.42
50-Day MA
$3.63
200-Day MA
$3.95
Volume
3,814,810.00
Analyst Price Targets
Low
$5.00
Consensus
$8.50
High
$12.00
(8 analysts)
Share Structure
Outstanding
85,578,052.00
Float
51,159,945.00
Free Float
59.8%
Normal free float
— 59.8% of shares trade freely, ~40.2% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-1.82
Stock Price: $4.13
EPS (Diluted): -2.27
EPS (Diluted): -2.27
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.56
Stock Price: $4.13
Total Equity: $78.09M
Shares: 72,947,927
Total Equity: $78.09M
Shares: 72,947,927
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.08
Market Cap: $353.44M
Total Debt: $1.11M
Cash: $85.41M
EBITDA: -$165.32M
Total Debt: $1.11M
Cash: $85.41M
EBITDA: -$165.32M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$196.6M
Market Cap: $353.44M
Total Debt: $1.11M
Cash: $85.41M
Total Debt: $1.11M
Cash: $85.41M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $4.13
Revenue: $0.00
Shares: 72,947,927
Revenue: $0.00
Shares: 72,947,927
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$172.50M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$165.67M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-134.1%
Net Income: -$165.67M
Total Equity: $78.09M
Total Equity: $78.09M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-106.6%
Operating Income: -$172.50M
Tax Rate: 0.0%
Equity: $78.09M
Total Debt: $1.11M
Cash: $85.41M
Tax Rate: 0.0%
Equity: $78.09M
Total Debt: $1.11M
Cash: $85.41M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.19
Current Assets: $142.02M
Current Liabilities: $64.80M
Current Liabilities: $64.80M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.01
Short-Term Debt: $1.11M
Long-Term Debt: $0.00
Total Debt: $1.11M
Total Equity: $78.09M
Long-Term Debt: $0.00
Total Debt: $1.11M
Total Equity: $78.09M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 72,947,927
Shares: 72,947,927
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.07
Total Equity: $78.09M
Shares: 72,947,927
Shares: 72,947,927
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.55
Operating CF: -$113.20M
CapEx: -$91,000
Shares: 72,947,927
CapEx: -$91,000
Shares: 72,947,927
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $4.13
Stock Price: $4.13
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$165.67M
Net Income: -$165.67M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares LRMR against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 10, 2026 1:48am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Expenses | $50.5M | $36.5M | $41.8M | $90.9M | $172.5M |
| Operating Income | -$50.5M | -$36.5M | -$41.8M | -$90.9M | -$172.5M |
| Net Income | -$50.6M | -$35.4M | -$36.9M | -$80.6M | -$165.7M |
| EBITDA | -$50.3M | -$35.0M | -$36.6M | -$80.3M | -$165.3M |
| EPS | $-2.93 | $-1.33 | $-0.84 | $-1.32 | $-2.27 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 10, 2026 1:48am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $70.1M | $26.8M | $26.7M | $33.2M | $85.4M |
| Total Current Assets | $72.2M | $120.7M | $90.2M | $195.3M | $142.0M |
| Total Assets | $78.7M | $126.4M | $95.9M | $200.2M | $145.8M |
| Current Liabilities | $8.8M | $10.7M | $9.5M | $24.4M | $64.8M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $14.3M | $15.5M | $14.2M | $28.4M | $67.8M |
| Total Equity | $64.4M | $110.9M | $81.7M | $171.8M | $78.1M |
| Retained Earnings | -$116.3M | -$151.6M | -$188.6M | -$269.2M | -$434.8M |
Cash Flow (Annual)
Last updated: Jul 10, 2026 1:48am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$42.1M | -$27.6M | -$33.5M | -$70.8M | -$113.2M |
| Capital Expenditure | $-333,000 | $-100,000 | $-163,999 | $-515,000 | $-91,000 |
| Free Cash Flow | -$42.4M | -$27.7M | -$33.6M | -$71.3M | -$113.3M |
| Acquisitions (net) | $-24,502 | $90,860 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $1.9M | -$43.3M | $-76,000 | $5.7M | $52.2M |
Analyst Estimates (Annual)
Last updated: Jul 10, 2026 1:48am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$57.1M $9.2M – $95.6M
|
$150.7M $149.8M – $151.6M
|
$330.9M $66.4M – $862.3M
|
$470.6M $94.4M – $1.2B
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$98.3M -$132.7M – -$63.8M
|
-$26.5M -$110.5M – $116.7M
|
$30.6M -$1.2M – $94.6M
|
$95.1M -$3.7M – $293.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 10, 2026 1:48am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | +27.6% | -14.3% | -117.7% | -89.8% |
| Net Income Growth | +30.2% | -4.5% | -118.1% | -105.5% |
| EBITDA Growth | +30.4% | -4.6% | -119.1% | -105.9% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-07-06 | Hamilton Thomas Edward | P-Purchase | 50,000.00 | $3.34 | $166,890 |
| 2026-05-19 | Flynn James E | A-Award | 55,150.00 | $3.33 | $183,650 |
| 2026-05-19 | LEFF JONATHAN S | A-Award | 55,150.00 | $3.33 | $183,650 |
| 2026-05-19 | SHERMAN JEFFREY W | A-Award | 55,150.00 | $3.33 | $183,650 |
| 2026-05-19 | Truitt Joseph | A-Award | 55,150.00 | $3.33 | $183,650 |
| 2026-05-19 | THOMAS FRANK E | A-Award | 55,150.00 | $3.33 | $183,650 |
| 2026-05-19 | Hamilton Thomas Edward | A-Award | 55,150.00 | $3.33 | $183,650 |
| 2026-02-27 | Flynn James E | P-Purchase | 1,084,012.00 | $5.00 | $5.4M |
| 2026-02-27 | Flynn James E | P-Purchase | 1,084,010.00 | $5.00 | $5.4M |
| 2026-02-27 | Flynn James E | P-Purchase | 831,978.00 | $5.00 | $4.2M |
| 2026-02-27 | Flynn James E | P-Purchase | 2,000,000.00 | $5.00 | $10.0M |
| 2026-02-27 | Hamilton Thomas Edward | P-Purchase | 100,000.00 | $5.00 | $500,000 |
| 2026-02-27 | THOMAS FRANK E | P-Purchase | 5,000.00 | $5.00 | $25,000 |
| 2026-02-27 | SHERMAN JEFFREY W | P-Purchase | 5,000.00 | $5.00 | $25,000 |
| 2026-01-26 | Shankar Gopi | A-Award | 153,822.00 | $3.60 | $553,759 |
| 2026-01-26 | Shankar Gopi | A-Award | 25,637.00 | $0.00 | $0 |
| 2026-01-26 | Clayton Russell | A-Award | 153,822.00 | $3.60 | $553,759 |
| 2026-01-26 | Clayton Russell | A-Award | 25,637.00 | $0.00 | $0 |
| 2026-01-26 | BEN-MAIMON CAROLE | A-Award | 600,600.00 | $3.60 | $2.2M |
| 2026-01-26 | BEN-MAIMON CAROLE | A-Award | 100,100.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for LRMR — it's generated by the pipeline (
market-narrative step).
No community reviews yet for LRMR.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.397 · fd27f02b · 2026-07-09 18:28:55